异柠檬酸脱氢酶1基因突变焦磷酸测序检测方法的建立

doi:10.3969/j.issn.1006-7795.2014.02.016

首都医科大学学报 ›› 2014, Vol. 35 ›› Issue (2): 219-224.doi: 10.3969/j.issn.1006-7795.2014.02.016

异柠檬酸脱氢酶1基因突变焦磷酸测序检测方法的建立

王丹慧, 蔡彦宁, 张燕莉, 高杰, 杨彩侠

首都医科大学宣武医院神经生物学研究室教育部神经变性病重点实验室北京市老年病医疗研究中心, 北京 100053

收稿日期:2014-01-03 出版日期:2014-04-21 发布日期:2014-04-16
基金资助:
国家自然科学基金（81071011），教育部新世纪优秀人才计划（NCET-10-013），北京市卫生系统高层次人才基金（008-0023）。

Establishment of pyrosequencing method to detect isocitrate dehydrogenase 1 mutations

Wang Danhui, Cai Yanning, Zhang Yanli, Gao Jie, Yang Caixia

Department of Neurobiology, Xuanwu Hospital, Capital Medical University, Key Laboratory for Neurodegenerative Diseases, Ministry of Education, Beijing Geriatric Medical Research Center, Beijing 100053, China

Received:2014-01-03 Online:2014-04-21 Published:2014-04-16
Contact: 蔡彦宁 E-mail:yanningcaimailbox@163.com
Supported by:
This study was supported by the National Natural Science Foundation of China(81071011), the Program for New Century Excellent Talents in University(NCET-10-0013), Beijing Health and Technical Personal of High-level Plan(008-0023).

摘要/Abstract

摘要：

目的建立异柠檬酸脱氢酶1（isocitrate dehydrogenase 1，IDH1）基因突变的焦磷酸测序检测方法，确定该方法的检测灵敏度。分析焦磷酸测序法与直接测序法对于鉴定IDH1突变的差异。方法构建携带野生型和突变型IDH1基因的质粒，使用质粒优化焦磷酸测序方法。使用已知比例的野生型和突变型质粒作为模版，确定突变的检测灵敏度。针对96例胶质瘤患者手术切除标本的基因组DNA，分别使用直接测序法和焦磷酸测序法，鉴定IDH1基因突变类型，并比较。结果使用焦磷酸测序能够检测到低至2%的IDH1突变。直接测序检出突变阳性率为32.3 %、焦磷酸测序检出突变阳性率为74.0 %。结论焦磷酸测序法检测IDH1基因突变灵敏可靠，适合临床分子诊断。

关键词: 异柠檬酸脱氢酶1, 焦磷酸测序法, 突变

Abstract:

Objective The present study aimed to establish a pyrosequencing method for IDH1 mutation examination, and quantify the sensitivity of this method. Furthermore, we tried to compare the differences between the direct sequencing and pyrosequencing for IDH1 mutation examination. Methods Plasmids carrying either wide-type or mutant IDH1 gene were constructed, and used to optimize the pyrosequencing method. The exact amount of mutant plasmids mixed with wide-type plasmids were served as templates for the pyrosequencing reaction to quantify the sensitivity of pyrosequencing based mutation examination. Both direct sequencing and pyroquencing methods were used to detect IDH1 mutations in 96 gliomas. Results Pyrosequencing detected as low as 2 % IDH1 mutation mixed in wide-type gene. Among the 96 glioma samples examined, 32.3% of the samples were identified as carrying IDH1 mutations based on direct sequencing, while 74.0% based on pyrosequencing method. Conclusion Pyrosequencing is a reliable and sensitive method in detecting IDH1 mutation, which is suitable for molecular diagnosis.

Key words: isocitrate dehydrogenase 1, pyrosequencing, mutation

中图分类号:

Q754

王丹慧, 蔡彦宁, 张燕莉, 高杰, 杨彩侠. 异柠檬酸脱氢酶1基因突变焦磷酸测序检测方法的建立[J]. 首都医科大学学报, 2014, 35(2): 219-224.

Wang Danhui, Cai Yanning, Zhang Yanli, Gao Jie, Yang Caixia. Establishment of pyrosequencing method to detect isocitrate dehydrogenase 1 mutations[J]. Journal of Capital Medical University, 2014, 35(2): 219-224.

参考文献

[1] 康春生, 浦佩玉.脑胶质瘤信号转导通路研究进展[J].中国现代神经疾病杂志, 2008, 8(5):388-392.

[2] Parsons D W, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme[J]. Science, 2008, 321(5897):1807-1812.

[3] Agarwal S, Sharma M C, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing[J]. Neuro Oncol, 2013, 15(6):718-726.

[4] 任晓辉, 崔向丽, 尚志梅, 等.少枝胶质肿瘤异柠檬酸脱氢酶1基因突变特点分析[J].中华医学杂志, 2012, 92(11):724-726.

[5] Jha P, Suri V, Sharma V, et al. IDH1 mutations in gliomas: first series from a tertiary care centre in India with comprehensive review of literature[J]. Exp Mol Pathol, 2011, 91(1):385-393.

[6] Bleeker F E, Lamba S, Leenstra S, et al. IDH1 mutations at residue p.R132(IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors[J]. Hum Mutat, 2009, 30(1):7-11.

[7] 郑勇, 王继超, 杨小朋, 等.不同病理级别胶质瘤细胞中IDH1基因变异表达观察[J].中国神经肿瘤杂志, 2012, 10(3):143-146.

[8] Yan H, Parsons D W, Jin G, et al. IDH1 and IDH2 mutations in gliomas[J]. N Engl J Med, 2009, 360(8):765-773.

[9] Gravendeel L A, Kloosterhof N K, Bralten L B, et al. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma[J]. Hum Mutat, 2010, 31(3):E1186-E1199.

[10] Nobusawa S, Watanabe T, Kleihues P, et al. IDH1 Mutations as molecular signature and predictive factor of secondary glioblastomas[J]. Clin Cancer Res, 2009, 15(19):6002-6007.

[11] Horbinski C, Kofler J, Kelly L M, et al. Diagnostic use of IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues[J]. J Neuropathol Exp Neurol, 2009, 68(12):1319-1325.

[12] 杨燕武, 谢飞, 汤俊佳, 等.IDH1 基因突变对胶质瘤诊断及预后意义[J].中国现代神经疾病杂志, 2012, 12(6):712-718.

[13] Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase Ⅲ trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide[J]. J Clin Oncol, 2009, 27(35):5874-5880.

[14] Houillier C, Wang X, Kaloshi G, et al. IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas[J]. Neurology, 2010, 75(17):1560-1566.

[15] 赵心同, 赵洪洋, 姚东晓, 等.脑胶质瘤治疗中自由基清除剂的价值[J].中华肿瘤防治杂志, 2011, 18(8):571-574.

[16] 孙增峰, 李文良, 谷峰, 等.胶质瘤耐药相关机制的研究进展[J].中华肿瘤防治杂志, 2011, 18(7):551-556.

[17] van den Bent M J, Hartmann C, Preusser M, et al. Interlaboratory comparison of IDH mutation detection[J]. J Neurooncol, 2013, 112(2):173-178.

[18] Patel K P, Barkoh B A, Chen Z, et al. Diagnostic Testing for IDH1 and IDH2 variants in acute myeloid leukemia and algorithmic approach using high-resolution melting curve analysis[J]. J Mol Diagn, 2011, 13(6):678-686.

[19] Tang J Y, Chang C C, Lin P C, et al. Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer[J]. Kaohsiung J Med Sci, 2012, 28(3):138-144.

[20] Blandine B, Yannick M. COLD PCR HRM: a highly sensitive detection method for IDH1 mutations[J]. Hum Mutat, 2010, 31(12):1360-1365.

异柠檬酸脱氢酶1基因突变焦磷酸测序检测方法的建立

Establishment of pyrosequencing method to detect isocitrate dehydrogenase 1 mutations

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	姚舒洋, 李小雪, 王淳秀, 张毅. 埃克替尼联合抗血管药物一线治疗EGFR突变晚期肺腺癌的单中心研究[J]. 首都医科大学学报, 2022, 43(2): 289-293.
[2]	熊枫然, 卢晶, 张英超, 谢荣荣, 赵儒轩, 李奇, 杨金奎. Kcnh6点突变单基因糖尿病家系的小鼠模型构建及表型分析[J]. 首都医科大学学报, 2021, 42(4): 575-581.
[3]	孙梦雪, 王雷明, 滕梁红. 胶质瘤中BRAF基因异常的研究进展[J]. 首都医科大学学报, 2020, 41(3): 380-384.
[4]	元沙沙, 马燕, 吴南楠, 许月超, 杨龙艳, 柯静, 赵冬. 妊娠期血糖异常者葡萄糖激酶基因突变筛查[J]. 首都医科大学学报, 2020, 41(1): 45-49.
[5]	张利强, 郑杰, 马洁, 陈振萍, 吴润晖. 9例具有致病基因变异的儿童期原发性血小板增多症临床分析[J]. 首都医科大学学报, 2018, 39(4): 607-611.
[6]	左灵坤, 阳荣辉, 马慧, 周萍, 孔璐. 生物信息学方法分析前列腺癌组织及细胞系中LMNA基因第七外显子点突变[J]. 首都医科大学学报, 2017, 38(6): 884-890.
[7]	姚舒洋, 支修益. 非小细胞肺癌术后辅助EGFR-TKI的治疗进展[J]. 首都医科大学学报, 2016, 37(6): 773-776.
[8]	曹曦, 谢荣荣, 信中, 杨金奎. 一例Kallmann综合征患者双基因突变分析[J]. 首都医科大学学报, 2014, 35(6): 765-770.
[9]	吴学宾. 慢性中性粒细胞白血病[J]. 首都医科大学学报, 2014, 35(5): 577-580.
[10]	张宁, 黄坚. Ⅱ型神经纤维瘤基因突变及表达与消化系统肿瘤[J]. 首都医科大学学报, 2014, 35(2): 257-260.
[11]	林媛;李积凤;刘杰;牛梦林;孙然;王军;刘岩;王辰;. Bβ448野生型及突变型纤维蛋白原稳定转染细胞系的建立[J]. 首都医科大学学报, 2012, 33(2): 187-192.
[12]	张婷;许强;杨紫伟;蒋素贞;鲁凤民;陈香梅;庄辉. 原发性肝细胞癌中乙型肝炎病毒基因整合的突变分析[J]. 首都医科大学学报, 2011, 32(3): 313-317.
[13]	张鑫#;武彦宁#;张大可;董培玲;范春蕾;李磊;丁惠国. 慢性HBV感染患者bcp/pc区点突变模式、pres区缺失及其临床意义[J]. 首都医科大学学报, 2011, 32(3): 324-330.
[14]	袁艳鹏;林庆玲;左晓虹;蔡彦宁. 基于等位基因特异性引物延伸的高分辨率熔解曲线基因分型方法的建立[J]. 首都医科大学学报, 2010, 31(6): 742-747.
[15]	姜鸾;邵蕾;胡旸;董凌月. 应用改良PCR法构建高GC含量启动子多位点定点突变载体[J]. 首都医科大学学报, 2010, 31(1): 88-92.